In response to existing and emerging challenges and gaps in chronic disease management, EPOS envisions to offer patients at risk to develop systemic malignancies and other multifactorial diseases, personalized and multimodality platforms for in vivo, minimally invasive, long term and sensitive detection, monitoring and intervention, significantly improving the patient prognosis and survival rates. Such platforms will pave the way to the multi-billion field of multifactorial disease molecular theranostics.